Benvenue Medical announces commercial availability of Luna 3D Interbody Fusion System

147

Benvenue Medical has announced the US commercial launch of their Luna 3D Interbody Fusion System, which it claims provides this least invasive approach to spinal fusion for treatment of symptomatic degenerative disc disease.

Luna 3D was cleared by the FDA in November 2014. Its full-scale launch follows a limited rollout in which >100 patient levels were treated by both open TLIF and minimally invasive approaches. According to Benvenue, it represents the next generation of expandable interbody fusion devices. The system was launched in conjunction with the North American Spine Society (NASS) Annual Meeting where it has received the 2015 Spine Technology Award for Luna in the Minimally Invasive Spine and Thoracolumbar Care categories. 

“Luna 3D is a significant improvement over other available static and expandable TLIF cages,” said Michael Wang, MD, chief of neurosurgery at University of Miami Health System. “Due to the implant’s cannula delivery, implantation is possible through a narrow surgical corridor, resulting in minimal nerve root retraction and tissue dissection.”

Luna 3D is a new expandable interbody designed for minimally invasive surgery (MIS), mini-open or open posterior approaches. Luna 3D’s controlled atraumatic insertion through a 6-8mm cannula is designed to minimise nerve retraction and mitigate implant migration. In-situ 3D expansion provides zero-impaction delivery, intended to preserve and protect vertebral endplates. Once in the disc space, Luna 3D expands to 25mm in diameter and up to 13mm in height. Bone graft is inserted into the Luna 3D cage after expansion.